ALSO READSun Pharmaceutical gets USFDA inspection report for Dadra facility Sun Pharma recalls 13,000 bottles of chewable Cetirizine for children in US Sun Pharma to create drug used for treatment of psoriasis, gets USFDA's nod Sun Pharma slips to Rs 424 cr Q1 loss on weak sales, anti-trust settlement Sun Pharma gains 4% as Dadra plant gets EIR from USFDA
Sun Pharmaceutical Industries on Thursday said its subsidiary has received approval from the US health regulator to market a generic version of GSK's Coreg CR, extended-release capsules in the American market. One of the company's wholly-owned subsidiaries has received final approval from US Food and Drug Administration (USFDA) for the generic product in strengths of 10mg, 20mg, 40mg and 80 mg, Sun Pharma said in a statement. Coreg CR extended-release capsules are indicated for treating various heart conditions, including heart failure and high blood pressure. As per IMS, Coreg CR had annual sales of around $208 million in the US for the 12 months ended August 2017. Sun Pharma shares were trading 2.32 per cent up at Rs 535.40 apiece on BSE today.